Gerlach, M.
Parkinson’s Disease and Related Disorders
1. Melvin Yahr (1917–2004). An appreciation
C. Powell
2. Melvin D. Yahr, 1917–2004. A personal recollection
H. Kaufmann
1.. Pathology
3. The discovery of dopamine deficiency in the parkinsonian brain
O. Hornykiewicz
4. Synchronizing activity of basal ganglia and pathophysiology of Parkinson’s disease
G. Heimer, M. Rivlin, Z. Israel, H. Bergman
5. Basal ganglia discharge abnormalities in Parkinson’s disease
T. Wichmann, M. R. DeLong
6. Bad oscillations in Parkinson’s disease
P. Brown
7. Cortical muscle coupling in Parkinson’s disease (PD) bradykinesia
M. J. McKeown, S. J. Palmer, W.-L. Au, R. G. McCaig, R. Saab, R. Abu-Gharbieh
8. GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons
R. E. Burke
9. The engrailed transcription factors and the mesencephalic dopaminergic neurons
D. Gherbassi, H. H. Simon
10. The role of Pitx3 in survival of midbrain dopaminergic neurons
S. M. Smits, M. P. Smidt
11. Genetic analysis of dopaminergic system development in zebrafish
S. Ryu, J. Holzschuh, J. Mahler, W. Driever
12. Striatal plasticity in parkinsonism: dystrophic changes in medium spiny neurons and progression in Parkinson’s disease
A. Y. Deutch
13. The nigrostriatal DA pathway and Parkinson’s disease
K. Fuxe, P. Manger, S. Genedani, L. Agnati
14. Relationship between axonal collateralization and neuronal degeneration in basal ganglia
M. Parent, A. Parent
15. Pathology associated with sporadic Parkinson’s disease — where does it end?
H. Braak, C. M. Müller, U. Rüb, H. Ackermann, H. Bratzke, R. A. I. Vos, K. Tredici
16. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson’s disease
G. M. Halliday, K. Tredici, H. Braak
17. A short overview on the role of a-synuclein and proteasome in experimental models of Parkinson’s disease
F. S. Giorgi, A. Bandettini di Poggio, G. Battaglia, A. Pellegrini, L. Murri, S. Ruggieri, A. Paparelli, F. Fornai
18. The role of protein aggregates in neuronal pathology: guilty, innocent, or just trying to help?
S. Gispert-Sanchez, G. Auburger
2.. Iron and neuromelanin
19. New face of neuromelanin
K. L. Double, G. M. Halliday
20. The effect of neuromelanin on the proteasome activity in human dopaminergic SH-SY5Y cells
W. Maruyama, M. Shamoto-Nagai, Y. Akao, P. Riederer, M. Naoi
21. Potential sources of increased iron in the substantia nigra of parkinsonian patients
M. Gerlach, K. L. Double, M. B. H. Youdim, P. Riederer
22. Iron and Friedreich ataxia
M. Pandolfo
3.. Genetics
23. Nongenetic causes of Parkinson’s disease
A. R. Chade, M. Kasten, C. M. Tanner
24. Is atypical parkinsonism in the Caribbean caused by the consumption of Annonacae?
A. Lannuzel, G. U. Höglinger, P. Champy, P. P. Michel, E. C. Hirsch, M. Ruberg
25. CYP450, genetics and Parkinson’s disease: gene × environment interactions hold the key
G. D. Mellick
26. Unique cytochromes P450 in human brain: implication in disease pathogenesis
V. Ravindranath, R. P. Kommaddi, H. V. Pai
27. Cytochrome P450 and Parkinson’s disease: protective role of neuronal CYP 2E1 from MPTP toxicity
C. Viaggi, C. Pardini, F. Vaglini, G. U. Corsini
28. Nicotine induces brain CYP enzymes: relevance to Parkinson’s disease
S. Miksys, R. F. Tyndale
29. Genetic causes of Parkinson’s disease: extending the pathway
O. Riess, R. Krüger, H. Hochstrasser, A. S. Soehn, S. Nuber, T. Franck, D. Berg
30. Progress in familial Parkinson’s disease
Y. Mizuno, N. Hattori, H. Yoshino, Y. Hatano, K. Satoh, H. Tomiyama, Y. Li
31. Molecular mechanisms of nigral neurodegeneration in Park2 and regulation of parkin protein by other proteins
N. Hattori, Y. Machida, S. Sato, K. Noda, M. Iijima-Kitami, S. Kubo, Y. Mizuno
32. Parkin and defective ubiquitination in Parkinson’s disease
T. M. Dawson
33. PINK-1 and DJ-1 — new genes for autosomal recessive Parkinson’s disease
P. Heutink
34. Clinical and pathologic features of families with
N. R. Whaley, R. J. Uitti, D. W. Dickson, M. J. Farrer, Z. K. Wszolek
35. Molecular genetic findings in LRRK2 American, Canadian and German families
T. Gasser
4.. Imaging
36. Genetic and DAT imaging studies of familial parkinsonism in a Taiwanese cohort
C. -S. Lu, Y. -H. Wu Chou, Y. -H. Weng, R. -S. Chen
37. Neuroimaging in Parkinson’s disease
W. Lokau, J. R. Adams, A. Troiano, A. J. Stoessl
38. Transcranial sonography in the early and differential diagnosis of Parkinson’s disease
D. Berg
5.. Models
39. How to judge animal models of Parkinson’s disease in terms of neuroprotection
E. C. Hirsch
40. Limitations of cellular models in Parkinson’s disease research
B. H. Falkenburger, J. B. Schulz
41. The Rotenone model of Parkinsonism — the five years inspection
G. U. Hoöglinger, W. H. Oertel, E. C. Hirsch
42. Controversies on new animal models of Parkinson’s disease Pro and Con: the rotenone model of Parkinson’s disease (PD)
W. J. Schmidt, M. Alam
43. Proposed animal model of severe Parkinson’s disease: neonatal 6-hydroxydopamine lesion of dopaminergic innervation of striatum
R. M. Kostrzewa, J. P. Kostrzewa, R. Brus, R. A. Kostrzewa, P. Nowak
44. a-Synuclein overexpression model
H. Mochizuki, M. Yamada, Y. Mizuno
45. Kynurenines, Parkinson’s disease and other neurodegenerative disorders: preclinical and clinical studies
H. Németh, J. Toldi, L. Vécsei
6.. Clinical approaches
46. What’s new? Clinical progression and staging of Parkinson’s disease
C. G. Goetz
47. Parkinson’s disease: premotor clinico-pathological correlations
E. Ch. Wolters, H. Braak
48. Detection of preclinical Parkinson’s disease along the olfactory trac(t)
H. W. Berendse, M. M. Ponsen
49. The clinical approach to gait disturbances in Parkinson’s disease; maintaining independent mobility
N. Giladi, Y. Balash
50. Getting around and communicating with the environment: visual cognition and language in Parkinson’s disease
I. Bodis-Wollner, M. -Y. Jo
51. Cardiovascular aspects of Parkinson disease
D. S. Goldstein
52. Multiple system atrophy and autonomic failure
C. J. Mathias
53. Sleep disturbances and excessive daytime sleepiness in Parkinson disease: an overview
C. L. Comella
54. Sleep and wakefulness disturbances in Parkinson’s disease
I. Arnulf
7.. Neuroinflammation
55. Parkinson’s disease dementia: what’s in a Lewy body?
D. J. Burn
56. Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of Interleukin 10
L. Qian, J. -S. Hong, P. M. Flood
57. Role of cytokines in inflammatory process in Parkinson’s disease
M. Sawada, K. Imamura, T. Nagatsu
8.. Neurosurgery
58. Surgical therapy for Parkinson’s disease
A. L. Benabid, S. Chabardès, E. Seigneuret, V. Fraix, P. Krack, P. Pollak, R. Xia, B. Wallace, F. Sauter
59. Deep brain stimulation for the treatment of Parkinson’s disease
C. Hamani, J. Neimat, A. M. Lozano
60. Deep brain stimulation in Parkinson’s disease patients: biochemical evidence
A. Stefani, E. Fedele, S. Galati, M. Raiteri, O. Pepicelli, L. Brusa, M. Pierantozzi, A. Peppe, A. Pisani, G. Gattoni, A. H. Hainsworth, G. Bernardi, P. Stanzione, P. Mazzone
61. Neurosurgery in Parkinson’s disease: the doctor is happy, the patient less so?
Y. Agid, M. Schüpbach, M. Gargiulo, L. Mallet, J. L. Houeto, C. Behar, D. Maltête, V. Mesnage, M. L. Welter
9.. L-Dopa
62. Placebo effect and dopamine release
R. Fuente-Fernández, S. Lidstone, A. J. Stoessl
63. A new look at levodopa based on the ELLDOPA study
S. Fahn
64. Thirty five years of experience in the treatment of Parkinson’s disease with levodopa and associations
C. Chouza, R. Buzó, A. Scaramelli, S. Romero, O. Medina, R. Aljanati, E. Dieguez, N. Lisanti, J. Gomensoro
10.. Neuroprotection
65. Concerning neuroprotective therapy for Parkinson’s disease
R. J. Uitti, Z. K. Wszolek
66. Triggering endogenous neuroprotective mechanisms in Parkinson’s disease: studies with a cellular model
M. J. Zigmond
67. Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression
M. Weinstock, L. Luques, C. Bejar, S. Shoham
68. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson’s disease
S. Gal, M. Fridkin, T. Amit, H. Zheng, M. B. H. Youdim
69. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety
O. Weinreb, T. Amit, O. Bar-Am, Y. Sagi, S. Mandel, M. B. H. Youdim
11.. Other treatment strategies
70. Anti-apoptotic gene therapy in Parkinson’s disease
J. B. Schulz
71. The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors
H. Kaufmann
12.. Dystonia
72. Pathophysiology of dystonia
M. Hallett
73. Genetics of dystonia
S. Bressman
DRM-restrictions
Printing: not available
Clipboard copying: not available
Keywords: MEDICAL / Public Health MED078000
- Author(s)
- Gerlach, M.
- Reichmann, H.
- Riederer, P.
- Youdim, M. B. H.
- Publisher
- Springer
- Publication year
- 2006
- Language
- en
- Edition
- 1
- Category
- Medicine, Health Care, Mode
- Format
- Ebook
- eISBN (PDF)
- 9783211452950